Medpace Holdings SEC Filings

Medpace Holdings (MEDP) disclosed insider transactions by President Jesse J. Geiger. On 10/27/2025, he exercised 19,460 stock options at $166.73 per share and sold 19,460 shares at a $605.12 weighted average price, with trades ranging from $600.00 to $610.66. On 10/29/2025, he exercised an additional 3,568 options at $166.73 and sold 3,568 shares at $585.

The option was reported as having vested in full on October 27, 2025. Following the transactions, 36,503 shares were reported as beneficially owned directly. The filing notes the sales were effected pursuant to a limit order placed during an open window period.

Medpace Holdings (MEDP): Form 4 insider transaction — On 10/27/2025, General Counsel & Corp. Secy. Stephen P. Ewald exercised 18,230 employee stock options at $166.73 and sold 15,230 shares of common stock at a weighted average price of $598.85 (transactions ranged from $596.25 to $602.955). Following these transactions, he beneficially owned 13,343 shares directly. The option was reported to have vested in full on October 27, 2025, and the derivative position was reduced to 0; the option carried an expiration date of 10/27/2026.

Medpace Holdings (MEDP): insider transaction — An executive officer sold common stock. On 10/27/2025, the Executive Vice President, Operations sold 2,000 shares in an open market transaction at a weighted average price of $605.01, with individual trades ranging from $605.00 to $605.13. The sale was executed via a limit order during an open window period. Following the sale, the officer beneficially owns 65,500 shares, held directly.

Medpace Holdings, Inc. reported strong quarterly results in its Q3 2025 10‑Q. Revenue reached $659.9 million, up 23.7% year over year, driven by growth in Metabolic, Oncology and CNS. Net income was $111.1 million and diluted EPS was $3.86. Operating income rose to $141.8 million as total operating expenses increased with higher reimbursed out‑of‑pocket and personnel costs.

For the first nine months, revenue was $1.82 billion with net income of $316.0 million and diluted EPS of $10.64. Operating cash flow was $520.6 million, while share repurchases totaled $912.9 million year to date, contributing to a decline in cash and equivalents to $285.4 million from $669.4 million at year‑end. The company ended the quarter with $3,000.6 million in backlog and net new awards of $789.6 million in Q3. The effective tax rate was 22.2% in the quarter, reflecting lower FDII benefits.

As of October 17, 2025, common shares outstanding were 28,168,223. The unsecured credit facility remained undrawn with $10.0 million available.

Medpace Holdings, Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.

The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" under the Exchange Act. MEDP’s common stock trades on the NASDAQ Global Select Market.

Robert O. Kraft, a director of Medpace Holdings, Inc. (MEDP), reported a securities transaction on 09/30/2025. The filing shows 57 restricted stock units vested and were reported as delivered, arising from a 227-unit grant made on 11/29/2024 that vests in four approximately equal installments on 03/31/2025, 06/30/2025, 09/30/2025 and 12/31/2025. Each restricted stock unit represents the right to receive one share of MEDP common stock. After the reported transaction the form lists 833 shares of common stock beneficially owned by the reporting person.

Cornelius P. McCarthy III, a director of Medpace Holdings, Inc. (MEDP), reported a vesting-related transaction dated 09/30/2025. 49 restricted stock units converted into 49 shares of common stock at $0 consideration, and the report shows the reporting person beneficially owns 10,246 shares following the transaction. The restricted stock units stem from a grant of 198 RSUs on 11/29/2024 that vest in four approximately equal installments on 3/31/2025, 6/30/2025, 9/30/2025, and 12/31/2025.

This Form 4 indicates a routine vesting event rather than an open-market purchase or sale; the transaction code is reported as "M" for vesting. The filing was signed by an attorney-in-fact on behalf of the reporting person.

Susan E. Burwig, Executive Vice President, Operations at Medpace Holdings, Inc. (MEDP), exercised employee stock options to acquire 10,000 shares on 09/26/2025 at an exercise price of $107.93 per share. The filing states the option vested in full on 02/28/2020. The Form 4 lists 67,500 shares as the amount of common stock beneficially owned following the non-derivative transaction and lists 30,984 shares as the number of derivative securities beneficially owned following the derivative transaction. The form is signed by an attorney-in-fact on behalf of Ms. Burwig on 09/30/2025.

Medpace Holdings insider transaction summary — An officer and director, Susan E. Burwig, reported a sale of 10,000 shares of Medpace common stock executed pursuant to a limit order during an open trading window; the reported weighted-average sale price was $480.00 (transactions ranged $480.00–$480.09). After the sale, the reporting person beneficially owned 57,500 shares. The filer notes availability of full pricing detail upon request. No derivative transactions or other changes in beneficial ownership are reported.